Self-assessment of success of early medical abortion using a self-performed urine pregnancy test. by Cameron, S. et al.
 1 
 
Abstract 
The European Society of Contraception Expert Group on Abortion identified as one 
of its priorities the need to disseminate up-to-date evidence-based information on 
the use of urine pregnancy tests by women for the self assessment of the success of 
early medical abortion. A concise communication was produced which summarises 
the latest research in an easy-to-read format suitable for busy clinicians. Information 
about individual urinary pregnancy tests is presented in boxes for ease of reference. 
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Background 
Simplifying early medical abortion (EMA) (< 10 weeks) is an important step in 
facilitating access to safe abortion.  This includes simplifying follow-up after medical 
abortion. Traditionally, a follow-up visit with the abortion provider was scheduled to 
confirm the success of the procedure  and this usually necessitated a routine 
ultrasound examination of the uterus to confirm that the pregnancy had been 
successfully terminated. Whilst ultrasound can reliably exclude a continuing 
pregnancy, ultrasonically visible but clinically unimportant blood and tissue 
commonly seen on ultrasound can lead to unnecessary intervention (1,2). The 
reliance on ultrasound also limits the range of providers and settings where this 
follow-up can take place. The reliance on ultrasound is also a disadvantage for 
women who live at a distance from an ultrasound facility. In addition, the need for 
multiple visits has been cited as a reason that women give for not choosing a medical 
method of abortion (3).  Multiple visits may create difficulties to get time off work or 
to get help with childcare. Women with mental health problems, those living in rural 
areas, those under coercive control and those from marginalised groups may be 
particular groups who find multiple visits problematic (4,5). Furthermore, studies 
report that approximately 50% of women do not attend a scheduled routine follow-
up visit and so get no confirmation that the pregnancy has been successfully 
terminated (6,7). 
Women value the opportunity to take more control over their treatment (8) and 
there is good evidence from both randomised controlled trials and observational 
studies that women can reliably determine the success of EMA based on a self-
assessment of   bleeding, presence / disappearance of pregnancy symptoms and the 
results of a self-performed urine pregnancy test (9,10,11). In addition, there is 
evidence that given the choice women preferentially opt for this  self- assessment 
option over a clinic follow-up (12,13).  
In many parts of Europe it is now possible for women who wish to have an EMA to 
make only a single visit to an abortion provider for assessment of gestation, receipt 
or provision of mifepristone and/or misoprostol (to self-administer at home), receipt 
and provision of effective ongoing contraception and instructions on how to self-
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assess the success of the abortion using a self-performed urinary pregnancy test 
(13,14). 
 
Types of urine pregnancy tests 
Low sensitivity urine pregnancy test (LSUPT) 
A LSUPT (detection limit 1000 IU) is already widely used throughout Europe and 
marketed for home use to confirm the success of EMA up to 9 weeks  (63 days) 
gestational age.  At two to three weeks post EMA, the urine level of human Chorionic 
Ggonadotrophin (hCG) will be less than 1000 IU in most women (90%) who have a 
successful expulsion  (7,12,15) (table 1).  Approximately 10% of women will have a 
positive LSUPT at two weeks; but of this group only 10% (i.e. 1% of all women) are 
subsequently shown to have an ongoing pregnancy (7,12,15). This means that use of 
the LSUPT can reduce the proportion of women requiring a follow-up clinical 
assessment / ultrasound to exclude or confirm an ongoing pregnancy from all 
women, to just one in ten women. 
Studies in a number of countries (including Europe, India and South Africa) have 
shown that women are able to use and interpret a LSUPT, includingeven those 
women with low literacy levels (9,10,11,13). The LSUPT (1000 IU) has not yet been 
evaluated for use with EMA beyond 9 weeks. 
 
 
High sensitivity urine pregnancy test (HSUPT) 
In contrast to the LSUPT, a ‘regular’ pregnancy test used to make the diagnosis of 
pregnancy (typical detection limit 10-25IU hCG) is highly sensitive and hence is 
known as also known as a high sensitivity urine pregnancy test (HSUPT). A HSUPT is 
of limited value for the purposes of self-assessment of the success of EMA as the 
HSUPT may remain positive for several weeks as it may take this time for hCG to fall 
beneath the low threshold level for a positive result (16). A HSUPT has been tested in 
studies to determine the usefulness to confirm the success of EMA, but 
approximately one quarter of HSUPT are still positive at one month  after treatment 
(17,18). 
 
Multilevel urine pregnancy test (MLUPT) 
A MLUPT that has a range of five thresholds of hCG (25, 100, 500, 2 000, 10 000 IU) 
has also been developed and can be used to determine the success of EMA (18). If 
conducted on the day of EMA and then if repeated (as early as three days later) and 
if the threshold of hCG that was formerly positive no longer tests positive, a 
significant decrease in hCG is assumed and ongoing pregnancy excluded. Studies 
from a number of countries have shown that a MLUPT with five windows is reported 
to be easy to use and interpret by women undergoing EMA (19). This MLUPT is not 
yet available in Europe. 
 
What to advise women 
Women should be advised that if they experience little or no bleeding after EMA or if 
they still have continuing pregnancy symptoms then they should contact their 
abortion provider as they may have an ongoing pregnancy. Studies have reported 
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that approximately one half of all ongoing pregnancies can be detected in this way at 
an early stage i.e. within two weeks of an EMA and before a LSUPT is scheduled (13).  
 
Counselling for self- assessment of success of EMA using a LSUPT 
Abortion providers who are considering introducing self-assessment of success of 
EMA with a LSUPT, may find it helpful to use a structured counselling proforma such 
as that shown in figure 1. 
 
Conclusion 
Women are able to determine the success of early medical abortion (EMA) 
themselves using a combination of signs, symptoms and a urine pregnancy test.  This 
simplifies EMA, expands the range of professionals able to provide EMA and most 
importantly gives women greater control over their bodies and treatment. 
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Table 1. Urine pregnancy tests for self assessment to exclude ongoing pregnancy 
after EMA 
 
 
Urine pregnancy test Key Features 
Low sensitivity urine pregnancy test 
(1000iu) 
 
 
 
High sensitivity urine pregnancy test (25-
50iu) 
 
 
 
 
Multi level urine pregnancy test  (range 
of levels) 
• Conduct at two weeks 
• Approx. 10% test positive 
• Available from abortion provider  
 
• Conduct at one month 
• Approx. 25 % test positive 
• Cheap, readily available in 
shops/pharmacies 
 
• Conduct before and after EMA 
• Can be used as early as three 
days  
• Multiple windows to read and 
interpret 
• Not currently available in EU 
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Figure 1. Example of a proforma that can be used for counselling women  
 
 I am  accepting responsibility to perform a ‘self assessment’ to exclude the 
possibility of an ongoing pregnancy  
 Signs that treatment may not have worked and that I may be pregnant are:  
o No bleed within 24 hours of receiving misoprostol  
o <4 days of bleeding  
o still ‘feel’ pregnant at the end of one week  or symptoms of pregnancy 
e.g. sore breasts, sickness, tummy growing etc. 
 In such circumstances I should contact the clinic immediately, as I may 
require more treatment to end the pregnancy 
 If the test is positive, or invalid, or I am unsure, I should contact the clinic as 
soon as possible to arrange for an appointment, as I might still be pregnant 
 
